Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 3/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424004 | 0.83 | PDCD1 (0.64) | PDCD1CD274APOBEC3GESR1ESR2 | |
| SCHEMBL25209196 | 0.83 | P2RX7 (0.38) | PDCD1CD274ALDH1A1GAAP2RX7 | |
| SCHEMBL30694686 | 0.82 | CD274 (0.65) | PDCD1CD274ALDH1A1KCNN4ACHE | |
| SCHEMBL15870721 | 0.79 | ACHE (0.39) | ALDH1A1GAAP2RX7SMN1; SMN2KCNN4 | |
| SCHEMBL5854222 | 0.79 | GABRA1 (0.46) | ALDH1A1GAAP2RX7SMN1; SMN2KCNN4 | |
| SCHEMBL14546326 | 0.77 | ACHE (0.37) | ALDH1A1GAAP2RX7SMN1; SMN2ACHE | |
| SCHEMBL11919553 | 0.77 | ACHE (0.37) | ALDH1A1GAAP2RX7SMN1; SMN2ACHE | |
| SCHEMBL31470109 | 0.77 | TAAR1 (0.46) | CD274P2RX7ACHETAAR1 | |
| SCHEMBL2449638 | 0.77 | TAAR1 (0.46) | CD274P2RX7ACHETAAR1 | |
| SCHEMBL1144270 | 0.77 | ACHE (0.37) | ALDH1A1GAAP2RX7SMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950478-B | Purine derivatives as NR2B negative modulators and their use as medicaments, in particular for the treatment of depressive disorders | 勃林格殷格翰国际有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4194452-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | Shanghai Zheye Biotechnology Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| EP-4180424-A1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-113950478-A | Purine derivatives as negative modulators of NR2B and their use as medicaments, in particular for the treatment of depressive disorders | 勃林格殷格翰国际有限公司 | 2022-01-18 | — | — | CN | disclosed |
| EP-3898632-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195499-A | Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection | 詹森药业有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020125730-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-25 | — | — | WO | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-8859776-B2 | Substituted piperidines that increase p53 activity and the uses thereof | MERCK SHARP & DOHME CORP. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2143714-B1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA CO (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | MERCK SHARP & DOHME LLC | 2012-08-16 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2143714-A1 | TETRAHYDROISOQUINOLINE COMPOUND | Kowa Company, Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | PDCD1 356/4885CD274 365/4885ALDH1A1 4211/4885 |
| US-20230165865-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | PDCD1 1889/4885CD274 3198/4885ALDH1A1 1615/4885 |
| US-20180162864-A1 | PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF AND COMPOSITIONS CONTAINING THE PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF | KRAS, DPYD, PSTPIP2 | PDCD1 109/4885CD274 1139/4885ALDH1A1 1400/4885 |
| US-20100120844-A1 | TETRAHYDROISOQUINOLINE COMPOUND | CCR3, CCR5, CCR1 | PDCD1 1804/4885CD274 1660/4885ALDH1A1 2938/4885 |
| US-20120208844-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | TP53, MDM2, TP53BP1 | PDCD1 2215/4885CD274 4454/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.